We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-9.2%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$707M
AUM Growth
-$184M
Cap. Flow
-$68.9M
Cap. Flow %
-9.74%
Top 10 Hldgs %
88.63%
Holding
27
New
1
Increased
–
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$10.7M

Top Sells

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$48.3M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$6.22M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$5.77M
4
CDTX
Cidara Therapeutics
CDTX
+$4.49M
5
REPL icon
Replimune Group
REPL
+$3.97M

Sector Composition

Rank Sector Weight
1 Healthcare 99.31%
2 Financials 0.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRVI icon
26
Trevi Therapeutics
TRVI
$2.57B
– –
-1,263,408
Closed -$1.77M
OBSV
27
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-999,364
Closed -$3.11M
1
2

Similar funds

PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return
GP
Gridiron Partners Wexford, Pennsylvania $164M AUM 3.31% 1-Year Est. Return
PWAM
Papamarkou Wellner Asset Management New York $164M AUM 25.23% 1-Year Est. Return
ACM
Alamar Capital Management Santa Barbara, California $164M AUM 19.77% 1-Year Est. Return

Omega Fund Management's Q4 2021 Portfolio in Review

As of Q4 2021, Omega Fund Management held 27 positions worth $707M, down 21% from $891M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Omega Fund Management withdrew a net $68.9M in Q4 2021, closing 5 positions and reducing 5 holdings. Its most notable exit was Atea Pharmaceuticals, an estimated $5.77M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

Against the trend, Omega Fund Management opened a new position in Theseus Pharmaceuticals, Inc. Common Stock worth $9.02M.

  • Omega Fund Management's largest Q4 2021 buy was Theseus Pharmaceuticals, Inc. Common Stock: 711,479 shares worth $9.02M.
  • Omega Fund Management's biggest Q4 2021 reduction was Nuvation Bio, cutting an estimated $48.3M.
  • Omega Fund Management fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $5.77M.
  • Omega Fund Management's ten largest holdings make up 89% of its $707M portfolio in Q4 2021.
  • Omega Fund Management opened 1 new position and closed 5 in Q4 2021.
  • Omega Fund Management's portfolio value fell 21% quarter-over-quarter to $707M.

Based on Omega Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.